For duodenal ulcers
For ulcers caused by H. Pylori infection and to prevent recurrences
For more information on other medications used to treat H. pylori, read the prospectus for each one.
Zollinger-Ellison syndrome where excess acid is produced in the stomach
You will need to see your doctor at regular intervals for the review of the dose and your symptoms if you are on long-term treatment.
Patients with liver problems
Consult your doctor, who will have special care in the initiation and during treatment with Rabeprazol Stada.
If you take more Rabeprazol Stada than you should
Do not take more tablets than prescribed per day. In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested. Always take the tablets and the carton box with you to the hospital so that the doctor knows what has been taken.
If you forget to take Rabeprazol Stada
If you interrupt treatment with Rabeprazol Stada
Relief of symptoms usually occurs before the ulcer has completely healed.It is essential not to interrupt treatment until your doctor tells you to.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine may cause side effects, although not everyone will experience them.
Stop taking Rabeprazol Stada and consult your doctor immediately if you notice any of the following side effects - you may need urgent medical treatment:
These side effects are rare (may affect up to 1 in 1,000 people).
These side effects are very rare (may affect up to 1 in 10,000 people).
Other possible side effects:
Frequent (may affect up to 1 in 10 people):
Less frequent (may affect up to 1 in 100 people):
Rare (may affect up to 1 in 1,000 people):
Unknown frequency (the frequency cannot be estimated from the available data):
If you take pantoprazole sodium for more than three months, it is possible that your magnesium levels in the blood will decrease. Low magnesium levels may manifest as fatigue, involuntary muscle contractions, disorientation, convulsions, dizziness, increased heart rate. If you experience any of these symptoms, please inform your doctor immediately. Low magnesium levels may also lead to a reduction in potassium or calcium levels in the blood. Your doctor may decide to perform periodic blood tests to monitor your magnesium levels.
Do not worry about the list of side effects. You may not experience any of them.
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this prospectus. You can also report them through the Spanish System for the Vigilance of Medicines for Human Use.https://www.notificaram.es.By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging. The expiration date is the last day of the month indicated.
Do not store at a temperature above 30 °C. Store in the original packaging to protect from light and moisture.
Do not use this medication if you observe the packaging damaged or with signs of manipulation.
Medications should not be disposed of through drains or in the trash. Dispose of the packaging and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. By doing so, you will help protect the environment..
Composition of Rabeprazol Stada
The active ingredient is rabeprazol sodium. Each Rabeprazol Stada 20 mg tablet contains 20 mg of rabeprazol sodium, equivalent to 18.85 mg of rabeprazol.
The other components are:
Tablet core:mannitol(E421), magnesium oxide(E530), hydroxypropylcellulose(E463), magnesium stearate(E572).
Intermediate layer:ethylcellulose(E462), heavy magnesium oxide(E530).
Tablet coating:hypromellose phthalate, dibutyl sebacate, iron oxide yellow (E172),titania dioxide (E171), talc.
Appearance of the product and contents of the packaging
Rabeprazol Stada 20 mg gastro-resistant tablets:yellow-colored tablets, coated with a film and round.
The packaging contains blisters of 1, 5, 7, 14, 15, 25, 28, 30, 50, 56, 75, 98 or 120 tablets.
Only some packaging sizes may be commercially marketed.
Holder of the marketing authorization and responsible manufacturer
Holder of the marketing authorization:
STADA Laboratory, S.L.
Frederic Mompou, 5
08960 Sant Just Desvern
(Barcelona)
Spain
Responsible manufacturer:
Laboratories Liconsa, S.A.
Avda. Miralcampo, Nº7,
Industrial Park Miralcampo
19200 Azuqueca de Henares (Guadalajara) Spain
Last review date of this leaflet:April 2023
The detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.